All News

The branded form of secukinumab is currently the only FDA-approved fully human biologic that directly inhibits interleukin-17A.

Abatacept is indicated across multiple inflammatory conditions, including for the treatment of adult patients with moderately to severely active rheumatoid arthritis, pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis, and active juvenile psoriatic arthritis.

The FDA granted Wezlana with interchangeable designation after clinical trials found no clinically significant differences in safety and efficacy for the indicated conditions across multiple inflammatory diseases.

Furmonertinib is in development for the treatment of advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

The Alliance for mRNA Medicines is the first and only scientific and policy organization singularly focused on advancing and advocating for global mRNA innovation.

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.

Collaboration to focus on enhancing physician engagement in clinical trials and cancer research.

The system was used by doctors at the Cleveland Clinic.

Collaboration to focus on advancing mRNA-based oncology therapeutics.

Company’s new leader previously served in the same role at OnQuality Pharmaceuticals.

Executive previously served as chief financial officer of Moderna, Amgen, and 3M.

KYV-101 designed as a CD19 CAR T-cell therapy.

Sapio chemistry solution unifies small-molecule and large-molecule discovery workflows on a single platform.

GC1126A is designed to treat the rare blood disorder.

Kalinovich previously worked at Wabtec as a corporate vice president.

The gastric/gastroesophageal cancer treatment is produced by Transcenta.

Exec joins the organization with decades of biopharma experience.

The company announced that it is fully funded beyond clinical Phase IIb ALS results.

The injector is designed for at-home or in-clinic use.

Copp comes to the company from McKinsey & Co.

EXXUA has been approved for treatment.

The company announced new hires for its chief scientific officer, chief business officer, and other leadership roles.

Hunt joins the company from HeartBeam.

Abrysvo reportedly reduces risk of condition in baby by 57% in the first six months after birth.

The treatment is approved for conditional marketing authorization.

Via Nova Therapeutics’ VNT-101 is an Influenza A nucleoprotein inhibitor.

The device, Maverick, utilizes Raman spectroscopy for bioprocess control.

Location aims to translate research into multiple real-world treatments.